Clinical trial
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating…
NCT00423696 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00423696 |
|---|---|
| Title | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
| Official title | Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Metastatic Colorectal Cancer [ACCORD] |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium |
| Enrollment | 145 |
| Start date | Mar 23, 2006 |
| Primary completion | Jul 28, 2008 |
| Completion | Aug 1, 2011 |
| First posted | Jan 18, 2007 |
| Last update posted | Feb 17, 2021 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: